Anti-Cancer Technology

 

Theralase® has a separate division for Photo Dynamic Technology that develops advanced pharmaceutical products and medical devices based on proprietary non-immunosuppressive photodynamic technology, targeting key health care and oncology markets.

The strategy is to build a specialty Biopharma company by developing and commercializing new and innovative products based on its patented photodynamic compounds, lasers, drug and light delivery systems, personalized and a patient specific platform technologies.

The strategy in oncology is to continue the research & development of the anti-cancer portfolio, with transition metal – based Photodynamic Compounds ("PDC") and other new anti-cancer products, and build a commercial platform in Canada and US for clinical use worldwide.

Theralase® Bladder Cancer Clinical Study

Our anti-cancer technology has now successfully completed a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer ("NMIBC"). We are currently designing a Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

In the following video Dr. Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of this clinical study.

 

For patients or practitioners wishing to get in touch with us about our Anti-Cancer Technology please click here!

Theralase® is listed on ClinicalTrials.gov

Our Partners in Innovation